Skip to content

Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting

Drug Utilization Evaluation Study of Ciprofloxacin Utilization and Adverse Events Occurrence in Community Pharmacy Setting: A Cross-Sectional Study

Status
Completed
Phases
Unknown
Study type
Observational
Source
ClinicalTrials.gov
Registry ID
NCT05916105
Enrollment
151
Registered
2023-06-23
Start date
2021-09-01
Completion date
2022-03-01
Last updated
2023-06-23

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Ciprofloxacin Adverse Reaction

Keywords

Ciprofloxacin, Use evaluation, Drug interaction

Brief summary

Background: Ciprofloxacin is a fluoroquinolone that is commonly used to treat a variety of diseases. Ciprofloxacin resistance is rising, resulting in suboptimal patient care. The goal of this study was to evaluate ciprofloxacin use in the community in terms of acceptable prescription, dose, frequency, and duration of use. Methods: A cross-sectional research was done in Egyptian community pharmacies by community pharmacists. Patients who were administered oral ciprofloxacin during the research period were included.

Detailed description

From September 2021 to February 2022, a cross-sectional, research was undertaken to evaluate ciprofloxacin usage. The investigation was carried out by community pharmacists in seven Egyptian community pharmacies. Data Collection: data gathered from pharmacy patients' records on a data collection form that included the factors indicated. The General Symptoms Questionnaire, physical examination, and blood testing were used to identify adverse occurrences. Study variables: * age, gender, pregnancy/lactation * Department/indication * Dose, Frequency, Duration, Adverse events, Drug interactions. Data was categorized and analyzed using appropriate software.

Interventions

Ciprofloxacin antibiotic

Sponsors

Damanhour University
Lead SponsorOTHER

Study design

Observational model
OTHER
Time perspective
RETROSPECTIVE

Eligibility

Sex/Gender
ALL
Age
18 Years to 80 Years

Inclusion criteria

* All ciprofloxacin included prescription during the study period.

Exclusion criteria

* un included ciprofloxacin prescription.

Design outcomes

Primary

MeasureTime frameDescription
Indications6 monthsAppropriate Indications of ciprofloxacin (frequency )
ciprofloxacin prescription (frequency )6 monthsNumber of appropriate ciprofloxacin prescription
adverse events6 monthsadverse events occured during ciprofloxacin therapy (frequency )

Countries

Egypt

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 4, 2026